Navigation Links
Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:12/2/2009

court judgment finding the patents invalid or not infringed or 30 months from the company's October 2009 receipt of a Paragraph IV certification letter from Teva.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL (armodafinil) Tablets [C-IV], TREANDA® (bendamustine hydrochloride) for Injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride), PROVIGIL® (modafinil) Tablets [C-IV] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
2. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
3. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
4. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
5. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
6. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
9. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
10. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
11. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... US Phase II Clinical Trials for Organ Transplantation, ... announces positive Phase I clinical results for,its transplantation ... clinical trials for organ transplantation. , Today LifeCycle ... I clinical trial program of LCP-Tacro, a,proprietary, once-daily ...
... Hemispherx Biopharma, Inc.,(AMEX: HEB), a biopharmaceutical company ... new drug entities for pandemic,disease threats, announced ... therapeutic product candidate Alferon-LDO in,combating highly pathogenic ... Alferon-LDO is a low-dose experimental oral formulation,of ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4
(Date:9/16/2014)... (PRWEB) September 16, 2014 SAMHSA, the federal ... mission a reduction of the impact of substance abuse and ... on the SAMHSA website in September is National Recovery Month, ... honor the gains made by those individuals in recovery. ... to addiction treatment in an effort to help those with ...
(Date:9/16/2014)... Using a pain clinic as a testing ground, researchers ... first popularized by Toyota in Japan can substantially reduce ... interns and residents. , In a report on the ... Medicine , the researchers adopted the so-called "Just-in-Time" training ... service industries to stem waste and keep complicated operations ...
(Date:9/16/2014)... R.I. (PRWEB) September 16, 2014 As ... Sunday, Sept. 14, through Saturday, Sept. 20, Amica ... sure children are safe and secure while in the ... the National Traffic Highway Safety Administration (NHTSA), 20 ... not read the instruction manual when installing child restraints. ...
(Date:9/16/2014)... 2014 Regulatory intelligence (RI), the ... has become a crucial skill for regulatory professionals ... sectors. Regulatory Intelligence 101 , new from ... serves as an essential guide to the basics ... examines available regulatory intelligence tools, both free and ...
(Date:9/16/2014)... Illegal drug use among teens in the United States is ... Encouragingly, the new study also found that alcohol use, ... people between the ages of 12 and 17 also dropped ... people aged 12 and older across the United States revealed ... among this age group also dropped from 8.9 percent to ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:RAPS Publishes Regulatory Intelligence 101 Book 2Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2
... apply the chemicals, study shows , THURSDAY, June 18 ... the normal risk of developing a precancerous blood disorder, ... undetermined significance) and characterized by an abnormal level of ... can lead to multiple myeloma, a cancer of the ...
... ... term, the continent’s healthcare leadership must be strengthened and expanded at the individual, institutional, ... ... -- To improve health outcomes in Africa over the long term, the continent’s healthcare ...
... up at night worrying whether they are going to develop diabetes ... middle age is a lifetime away. As it ... School of Medicine have found that young adults (18 to 30 ... treadmill test -- are two to three times more likely to ...
... Arnhem, June 2009 The 4th ESU Master class ... the European School of Urology (ESU) on 27-28 June ... The format consists of three modules. Module 1 is ... ,Immunotherapy and targeted therapies, and module 3 ,Systemic cytotoxic ...
... (OTC Bulletin Board: BHRT) a company committed to delivering ... treat heart failure and cardiovascular diseases announced today that ... systems at the American Association of Heart Failure Nurses ... place from June 25 - 27, 2009 at the ...
... , ... present never-before released results from two annual surveys at the upcoming DIA Meeting in ... ... for clinical trials information, will present never-before released results from two annual surveys aimed ...
Cached Medicine News:Health News:Pesticides Linked to Blood Disorder 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 3Health News:Aerobically unfit young adults on road to diabetes in middle age 2Health News:4th ESU master class on medical treatment for urological cancer held in Barcelona, Spain 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 3Health News:CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting 2
Lombart clip-on occluder...
9 inch double ended with one end black and the other end with 49 holes...
Double Ended Occluders...
Long handle occluders are approximately 9 inches long....
Medicine Products: